CA2384525C - Thienylhydrazone possedant des proprietes analogues a celles de la digitale (effets inotropes positifs) - Google Patents

Thienylhydrazone possedant des proprietes analogues a celles de la digitale (effets inotropes positifs) Download PDF

Info

Publication number
CA2384525C
CA2384525C CA002384525A CA2384525A CA2384525C CA 2384525 C CA2384525 C CA 2384525C CA 002384525 A CA002384525 A CA 002384525A CA 2384525 A CA2384525 A CA 2384525A CA 2384525 C CA2384525 C CA 2384525C
Authority
CA
Canada
Prior art keywords
lassbio
pharmaceutical composition
patient
use according
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002384525A
Other languages
English (en)
Other versions
CA2384525A1 (fr
Inventor
Eliezer J. De Barreiro
Roberto Takashi Sudo
Edson X. Albuquerque
Yasco Aracava
Paulo De Assis Melo
Gisele Zapata Sudo
Newton Goncalves De Castro
Carlos Alberto Manssour Fraga
Wagner Monteiro Cintra
Francois Germain Noel
Claudia Lucia Martins Da Silva
Patricia Dias Fernandes
Ana Luisa Palhares De Miranda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade Federal do Rio de Janeiro UFRJ
University of Maryland at Baltimore
Original Assignee
Universidade Federal do Rio de Janeiro UFRJ
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal do Rio de Janeiro UFRJ, University of Maryland at Baltimore filed Critical Universidade Federal do Rio de Janeiro UFRJ
Publication of CA2384525A1 publication Critical patent/CA2384525A1/fr
Application granted granted Critical
Publication of CA2384525C publication Critical patent/CA2384525C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule (I), dans laquelle R1 est sélectionné dans le groupe constitué par hydrogène, alkyle doté de 1 à 6 atomes de carbone, phényle non substitué et phényle substitué ; R2 est sélectionné dans le groupe constitué par H, alcène, phénol non substitué et phényle substitué ; et des sels pharmaceutiquement acceptables de ce composé qui possèdent des propriétés analogues à celles de la digitale. L'invention concerne en outre un nouveau procédé de synthèse de 3,4-méthylènedioxybenzoyl-2-thiénylhydrazone (LASSBio-294). LASSBio-294 a un effet positif inotrope sur les muscles cardiaque et squelettiques. L'invention est utile dans le traitement d'insuffisance cardiaque congestive et de fatigue musculaire. Elle ne comporte pas les effets toxiques observés chez des glycosides de digitale.
CA002384525A 1999-06-21 2000-06-21 Thienylhydrazone possedant des proprietes analogues a celles de la digitale (effets inotropes positifs) Expired - Fee Related CA2384525C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14035299P 1999-06-21 1999-06-21
US60/140,352 1999-06-21
PCT/US2000/017024 WO2000078754A1 (fr) 1999-06-21 2000-06-21 Thienylhydrazone possedant des proprietes analogues a celles de la digitale (effets inotropes positifs)

Publications (2)

Publication Number Publication Date
CA2384525A1 CA2384525A1 (fr) 2000-12-28
CA2384525C true CA2384525C (fr) 2007-03-06

Family

ID=22490853

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002384525A Expired - Fee Related CA2384525C (fr) 1999-06-21 2000-06-21 Thienylhydrazone possedant des proprietes analogues a celles de la digitale (effets inotropes positifs)

Country Status (4)

Country Link
EP (1) EP1532140A1 (fr)
AU (1) AU5628700A (fr)
CA (1) CA2384525C (fr)
WO (1) WO2000078754A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0403363A (pt) * 2004-08-20 2006-05-02 Univ Rio De Janeiro relaxantes musculares seletivos e composições farmacêuticas
BRPI0601885A (pt) * 2006-05-15 2008-03-25 Univ Rio De Janeiro composição farmacêutica antiinflamatória e analgésica contendo derivados n-acilidrazÈnicos do safrol, uso, e processo para sua preparação
WO2008095328A1 (fr) * 2007-01-31 2008-08-14 Guangzhou Zhongwei Biotechnology Ltd Sorte de poudre de piperphentonamine hydrochlorique lyophilisée pour injections, son procédé de préparation et ses utilisations
CN103304561B (zh) * 2013-06-21 2016-06-01 天津药物研究院 一类具有抗血栓作用的化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410540A (en) * 1981-11-04 1983-10-18 Merrell Dow Pharmaceuticals Inc. Cardiotonic 4-aroylimidazolidin-2-ones
CA1266268C (fr) * 1985-10-15 1990-02-27 Aroylthiazolones cardiotoniques

Also Published As

Publication number Publication date
CA2384525A1 (fr) 2000-12-28
WO2000078754A1 (fr) 2000-12-28
AU5628700A (en) 2001-01-09
EP1532140A1 (fr) 2005-05-25

Similar Documents

Publication Publication Date Title
KR880000042B1 (ko) 신규 유기 아마이드 화합물의 제법
WO2012129495A1 (fr) Ligands de récepteurs opïoides, et leurs procédés d'utilisation et de production
CH647757A5 (fr) Derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee.
JP2021534249A (ja) ３−アリールオキシ−３−アリール−プロピルアミン化合物およびその用途
EA005378B1 (ru) Аминированные производные дигидро-1,3,5-триазина и их применение в терапии
RU2036922C1 (ru) Производные 1,4-дигидропиридина или их гидрохлориды, обладающие антагонистическими свойствами по отношению к ионам кальция
IL228630A (en) Compounds for the treatment of metabolic syndrome and intermediates for the synthesis of these compounds
JP2012519193A (ja) テトラヒドロ−イミダゾ［１，５−α］ピラジン誘導体塩、その製造方法及び医薬用途
CN109734701A (zh) Rock抑制剂-二氯乙酸复盐及其制备方法和用途
CN102225940A (zh) 一种苯甲酸异山梨醇酯类化合物、其制备方法及医药用途
CA2384525C (fr) Thienylhydrazone possedant des proprietes analogues a celles de la digitale (effets inotropes positifs)
KR100919723B1 (ko) 글루타민 프럭토즈-6-포스페이트 아미도전이효소(ｇｆａｔ)억제제
AU2011360973A1 (en) Compounds and methods for the treatment of pain and other disorders
US7091238B1 (en) Thienylhydrazon with digitalis-like properties (positive inotropic effects)
JP5903166B2 (ja) ブチルフタリドの誘導体、並びにその製造法及び使用
EP0262053A2 (fr) Nouveaux dérivés d'amino-acides, leur procédé de préparation et compositions pharmaceutiques les contenant
CA2629738A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant
KR102383733B1 (ko) 세스퀴테르펜 유도체를 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학적 조성물
DE69402004T2 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen
WO2012056976A1 (fr) Modulateur de l'activité de l'adénylate cyclase
Braquet et al. Effect of platelet-activating factor on platelets and vascular endothelium
RU2081869C1 (ru) Производные 1,4-дигидропиридина и фармацевтическая композиция на их основе, обладающая вазоактивным действием
US4788301A (en) Novel allylic amines
JPH07502273A (ja) ベンゾピラン　クラス３抗不整脈薬
JP2022537518A (ja) 脳神経または心臓保護剤としてのアミノチオール系化合物の使用

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed